Aerosolized Alpha-1 antitrypsin: Phase II/III final data

Final data from a double-blind, European and Canadian Phase II/III trial in 168 patients with AAT deficiency showed that twice-daily 160 mg inhaled AAT for 50 weeks missed the secondary endpoints of reducing the time to first event-based exacerbation with a severity of mild, moderate or severe (p=not significant) and of a lower rate of first severe exacerbation events (18.8% vs. 31.1%, p=not significant)

Read the full 649 word article

User Sign In